PRMT1 and neoplasm: Intensive studies on solid tumors and hematologic malignancies have revealed that PRMT1 is overexpressed or aberrantly spliced in breast, prostate, lung, colon, bladder, and gastric cancers, as well as leukemia [18,19], and its catalytic epigenetic transcriptional activation marker correlates with tumor grade and overall prognosis of solid tumors (Table 1).